TruTrace Technologies (CSE: TTT- OTCQB: TTTSF) CEO Robert Galarza joined Steve Darling from Proactive to bring news the company has announced that it has signed a letter of intent with Georgia-based PharmaCentra to support a clinical trial ecosystem built on standardized protocols and testing of cannabis products for use in the medical industry.
Galarza sharing with Proactive this is a very important step for cannabis, which is a useful component of therapies to treat serious conditions because it ensures all products will be safe and consistent.